Literature DB >> 8809524

Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study.

P M Elliott1, J C Kaski, K Prasad, H Seo, A K Slade, J H Goldman, W J McKenna.   

Abstract

Patients with hypertrophic cardiomyopathy frequently complain of chest pain during daily activities. ST-segment depression is described in association with sudden death and pacing, but its prevalence during ambulatory electrocardiographic monitoring is unknown. The aim of this study was to determine the relation of ambulatory ST-segment depression to clinical characteristics, risk factors for sudden death and thallium-201 perfusion in patients with hypertrophic cardiomyopathy. Continuous 48 h ambulatory electrocardiographic monitoring was performed in 113 patients (age 38 +/- 14 years) with hypertrophic cardiomyopathy. Ninety-four (83%) recordings were suitable for ST-segment analysis. A total of 109 episodes of ST-segment depression (> or = 1 mm from baseline) were recorded in 25 (27%) patients (mean 4 +/- 5). In patients < or = 30 years of age (but not > 30) there was an association between ST-segment depression and a history of exertional chest pain (seven of 12 vs one of 20; P = 0.001), and dyspnoea NYHA class II/III (seven of 15 vs one of 17; P = 0.008). There was no association between ST-segment depression and risk markers for sudden death, i.e. family history of sudden death, syncope and non-sustained ventricular tachycardia, in any group. Reversible thallium-201 defects occurred in 27 (29%) of the 94 patients with analysed recordings but were not associated with symptoms, risk factors for sudden death or ambulatory ST-segment depression. In young patients with hypertrophic cardiomyopathy, ischaemia-like ST-segment depression is common and is associated with a history of typical angina and dyspnoea. Reversible thallium-201 perfusion defects are associated with neither symptomatic status nor ambulatory ST-segment depression.

Entities:  

Mesh:

Year:  1996        PMID: 8809524     DOI: 10.1093/oxfordjournals.eurheartj.a015002

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

Review 1.  Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Aurelio Sgalambro; Massimo Baldi; Barbara Sotgia; Davide Antoniucci; Paolo G Camici; Roberto Sciagrà; Iacopo Olivotto
Journal:  J Cardiovasc Transl Res       Date:  2009-11-03       Impact factor: 4.132

2.  Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study.

Authors:  Roberto Sciagrà; Raffaella Calabretta; Fabrizio Cipollini; Alessandro Passeri; Angelo Castello; Franco Cecchi; Iacopo Olivotto; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-03       Impact factor: 9.236

Review 3.  Hypertrophic cardiomyopathy: management issues in the new millennium.

Authors:  Rajesh Thaman; Sami Firoozi; M S Hamid; William J McKenna
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 4.  The role of exercise testing in the evaluation of the patient with hypertrophic cardiomyopathy.

Authors:  S Firoozi; S Sharma; W J McKenna
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

5.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

6.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

7.  Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study.

Authors:  Rulan S Parekh; Lucy A Meoni; Bernard G Jaar; Stephen M Sozio; Tariq Shafi; Gordon F Tomaselli; Joao A Lima; Larisa G Tereshchenko; Michelle M Estrella; W H Linda Kao
Journal:  BMC Nephrol       Date:  2015-04-24       Impact factor: 2.388

Review 8.  Hypertrophic Cardiomyopathy-Past, Present and Future.

Authors:  Alphonsus C Liew; Vassilios S Vassiliou; Robert Cooper; Claire E Raphael
Journal:  J Clin Med       Date:  2017-12-12       Impact factor: 4.241

Review 9.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

10.  Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.

Authors:  Claudia Camaioni; Kristopher D Knott; Joao B Augusto; Andreas Seraphim; Stefania Rosmini; Fabrizio Ricci; Redha Boubertakh; Hui Xue; Rebecca Hughes; Gaby Captur; Luis Rocha Lopes; Louise Anne Elizabeth Brown; Charlotte Manisty; Steffen Erhard Petersen; Sven Plein; Peter Kellman; Saidi A Mohiddin; James C Moon
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.